# Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)

> **NCT03002818** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 41 (actual)

## Conditions studied

- Chronic Hepatitis C Virus (HCV)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03002818
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-01
- **Primary completion:** 2018-04-25
- **Final completion:** 2018-04-25
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03002818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03002818, "Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03002818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*